Welcome to our dedicated page for BioRestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies stock.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a cutting-edge biotechnology company based in the United States, dedicated to developing regenerative medicine products and therapies using cell and tissue protocols, particularly involving adult stem cells. The company’s core focuses are its Disc/Spine Program and Metabolic Program.
In the Disc/Spine Program, their lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. This innovative treatment is designed for the non-surgical management of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRTX-100 undergoes a meticulous production process, starting from the collection of a patient’s bone marrow, followed by the isolation and culturing of stem cells, and finally cryopreserving these cells. The therapy involves injecting BRTX-100 into the patient's damaged disc, offering hope for patients whose pain has not been alleviated by other non-invasive treatments.
The Metabolic Program focuses on developing cell-based therapies to combat obesity and metabolic disorders using brown adipose-derived stem cells. This innovative approach aims to generate brown adipose tissue to help address these widespread health issues.
BioRestorative Therapies is also venturing into the rapidly growing bio-cosmeceutical market. The company recently signed a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a prominent North American aesthetics company. This partnership aims to introduce proprietary cell-based innovations to the aesthetics market, leveraging both BioRestorative’s expertise in cell-based biologics and Cartessa’s strong market presence.
Financially, BioRestorative is strong, ending 2023 with around $11.1 million in cash and cash equivalents, and an additional $7.6 million from a recent private placement. This solid financial standing, combined with expected revenues from its new commercial products, allows the company to pursue further advancements in their clinical and preclinical pipelines, including their BRTX-100 and ThermoStem® programs.
For more information, visit BioRestorative Therapies or contact Investor Relations at ir@biorestorative.com.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) has signed a Master Service Agreement with PRC Clinical to manage its Phase 2 clinical trial for BRTX-100, aimed at treating chronic lumbar disc disease. PRC Clinical brings extensive experience and innovative technology to the collaboration. CEO Lance Alstodt emphasized this partnership as a significant step towards clinical development. The trial's success could advance BioRestorative's mission to develop cell-based therapeutics, as they aim for primary endpoint readouts in the near future.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced that CEO Lance Alstodt will appear on the NewMedia Show on December 21, 2021. The show features discussions on various topics, leveraging a broad audience across social media platforms, including YouTube and LinkedIn. Alstodt expressed excitement to share the company’s 2021 achievements and future plans. BioRestorative specializes in adult stem cell-based therapies and is developing treatments for disc/spine disease and metabolic disorders, notably BRTX-100 for chronic lower back pain.
BioRestorative Therapies (NASDAQ: BRTX) recently shared a year-end update reflecting on 2021's achievements and 2022 goals. The company raised $23 million through a capital raise, enabling it to fund its Phase 2 clinical trial for BRTX-100, targeting chronic lumbar disc disease. Major milestones included uplisting to the Nasdaq, eliminating all debt, and restructuring operations. Looking ahead, BioRestorative aims to enroll patients for the BRTX-100 trial and further develop its products, particularly its ThermoStem® program.
BioRestorative Therapies, Inc. (NASDAQ:BRTX) has filed ten patent applications with the USPTO relating to its BRTX-100 program aimed at treating chronic lumbar disc disease. The patents focus on manufacturing methods for stem cells that can survive in low-oxygen environments, crucial for effective therapy. This strengthens the company's intellectual property portfolio. BioRestorative is FDA-authorized to begin a Phase 2 clinical trial for BRTX-100.
BioRestorative Therapies (NASDAQ:BRTX) has signed a letter of intent with PRC Clinical to provide startup CRO services for its BRTX-100 Phase 2 trial. This trial aims to treat chronic lumbar disc disease using an innovative stem cell therapy. PRC Clinical brings 20 years of experience in clinical trial management, enhancing patient enrollment and site monitoring. The collaboration marks a significant step towards FDA validation of their technology. CEO Lance Alstodt highlighted the importance of this partnership in updating shareholders throughout the regulatory process.
BioRestorative Therapies (NASDAQ:BRTX) announces the appointment of Robert Kristal as Chief Financial Officer. Kristal, with extensive experience in corporate finance and strategic collaborations, aims to enhance the company's financial strategy and communication with public markets. His role comes at a critical time as BioRestorative prepares to initiate clinical trials following a successful restructuring into a debt-free entity. The company is focused on developing innovative therapies, notably BRTX-100 for disc disorders and ThermoStem for metabolic conditions.
BioRestorative Therapies (NASDAQ: BRTX) announced the closing of a public offering, raising approximately $23 million by issuing 2,300,000 units priced at $10.00 each. Each unit includes one share of common stock and a warrant to purchase an additional share at the same price, exercisable immediately for five years. The offering's proceeds will support BRTX's clinical programs in stem cell-based treatments for spinal and metabolic disorders. The company's stock was recently listed on the Nasdaq Capital Market.
BioRestorative Therapies, Inc. (NASDAQ: BRTX) has announced a public offering of 2,300,000 units, priced at $10.00 each, consisting of common stock and warrants. The offering is projected to raise gross proceeds of $23 million. This marks a significant milestone as the company's common stock will begin trading on The Nasdaq Capital Market under the ticker symbol 'BRTX' from November 5, 2021. The offering is expected to close around November 9, 2021, and includes an option for underwriters to purchase up to 345,000 additional shares. Funds raised aim to enhance the company’s financial position.
BioRestorative Therapies (BRTX) announced a 1-for-4,000 reverse stock split to facilitate its planned listing on The Nasdaq Capital Market. The split is effective from October 27, 2021, with the temporary ticker symbol BRTXD. Following the split, outstanding shares will decrease from approximately 3.49 billion to 872,211. The company believes this action meets Nasdaq's initial listing requirements, enhancing its appeal to institutional investors and access to capital.
BioRestorative Therapies, Inc. (OTC: BRTX) announced the nomination of Patrick F. Williams and David Rosa to its Board of Directors. This strategic move reflects the company's aim to enhance leadership with experienced professionals in the medical device industry. Williams, CFO at STAAR Surgical, and Rosa, CEO of NeuroOne, will bring valuable expertise to support BioRestorative's focus on cell therapies and overall growth. Their election is contingent upon the effectiveness of the company’s pending registration statement.
FAQ
What is the current stock price of BioRestorative Therapies (BRTX)?
What is the market cap of BioRestorative Therapies (BRTX)?
What does BioRestorative Therapies, Inc. specialize in?
What are the main programs developed by BioRestorative Therapies?
What is BRTX-100?
How does BRTX-100 work?
What recent partnership has BioRestorative Therapies entered into?
How financially stable is BioRestorative Therapies?
What are the potential benefits of the partnership with Cartessa Aesthetics?
What is the focus of BioRestorative's Metabolic Program?
Who can I contact for investor relations at BioRestorative Therapies?
Where can I find more information about BioRestorative Therapies?
